Condition
Obesity
Locations
Denmark
Start date
10/04/2026
Identifiers
Trial ID NN9838-8411,
NCT number NCT07527195,
Eudract number Not Available
NCT number NCT07527195,
Eudract number Not Available
Summary
The purpose of this clinical study is to look into how study medicines CagriSema (cagrilintide and semaglutide), cagrilintide, and semaglutide affects muscle health in people with excess body weight and slightly higher than normal blood sugar as they lose weight. Participants will either get CagriSema (a new study drug), cagrilintide (a new study drug), semaglutide (a drug that doctors can already prescribe to treat people with type 2 diabetes and excess body weight) or placebo (a placebo looks like the treatment being tested but doesn't have any active ingredients in it). Which treatment participants will get is decided by chance. Participants will be in this clinical study up to 15 months.
Trial Overview:
Treatment
DRUG: Cagrilintide
DRUG: Semaglutide
DRUG: Placebo cagrilintide
DRUG: Placebo semaglutide
Study type
INTERVENTIONAL
Trial duration
Apr 10 2026 - Jun 09 2028
Participants
100
Phase
I
Are you eligible?
Gender
Male and female
Age
50 to 70 years old
Find out how you can participate
Questions or concerns
Do you have any question about what it’s like being a clinical volunteer? Have a look at our answers to frequently asked questions.
This site contains information about clinical trials sponsored by Novo Nordisk. It is not intended to replace the advice of a healthcare professional and should not be construed as providing advice or making a recommendation. The information on this site should not be relied on as the basis for any decision or action. Only a physician can determine whether a specific product is correct for a particular patient. If you have questions regarding any information contained on this site you should consult a physician.